HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Learn More

YMAB

Y-Mabs Therapeutics Inc

Last Close
Sep 15  •  04:00PM ET
8.61
Dollar change
0.00
Percentage change
0.00 %
Healthcare • Biotechnology • USA • NASD
Peers: BMRN CLLS BLUE ADAP AGEN SRPT MRNA GSK TGTX XOMA
 | Held by: VTI IWM VXF IWO IBB VTWO SCHA VHT ITOT IWC
Scroll to Statements
IndexRUT P/E- EPS (ttm)-0.49 Insider Own24.10% Shs Outstand45.44M Perf Week0.23%
Market Cap391.22M Forward P/E- EPS next Y-0.90 Insider Trans0.00% Shs Float34.49M Perf Month1.18%
Enterprise Value332.05M PEG- EPS next Q-0.22 Inst Own71.30% Short Float5.37% Perf Quarter82.80%
Income-22.22M P/S4.58 EPS this Y-14.48% Inst Trans38.23% Short Ratio2.08 Perf Half Y84.37%
Sales85.39M P/B4.47 EPS next Y-17.73% ROA-17.01% Short Interest1.85M Perf YTD9.96%
Book/sh1.93 P/C6.28 EPS next 5Y-9.60% ROE-24.31% 52W High16.11 -46.55% Perf Year-35.12%
Cash/sh1.37 P/FCF- EPS past 3/5Y19.44% 21.90% ROIC-24.66% 52W Low3.55 142.54% Perf 3Y-47.88%
Dividend Est.- EV/EBITDA- Sales past 3/5Y35.95% - Gross Margin81.73% Volatility0.19% 0.20% Perf 5Y-78.82%
Dividend TTM- EV/Sales3.89 EPS Y/Y TTM11.93% Oper. Margin-31.21% ATR (14)0.09 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.58 Sales Y/Y TTM-1.34% Profit Margin-26.03% RSI (14)81.20 Recom2.92
Dividend Gr. 3/5Y- - Current Ratio4.00 EPS Q/Q65.97% SMA200.61% Beta0.49 Target Price9.54
Payout- Debt/Eq0.04 Sales Q/Q-14.36% SMA5025.84% Rel Volume0.00 Prev Close8.61
Employees107 LT Debt/Eq0.03 EarningsAug 08 BMO SMA20040.75% Avg Volume892.30K Price8.61
IPOSep 21, 2018 Option/ShortYes / Yes EPS/Sales Surpr.73.38% 3.55% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Apr-22-25Downgrade BofA Securities Neutral → Underperform $3
Nov-18-24Initiated Oppenheimer Outperform $23
Aug-16-24Initiated Cantor Fitzgerald Overweight $20
Jun-28-24Initiated Truist Buy $21
May-10-23Upgrade Wedbush Neutral → Outperform $5 → $13
Apr-03-23Downgrade Guggenheim Buy → Neutral
Jan-27-23Downgrade Morgan Stanley Equal-Weight → Underweight $4
Jan-05-23Downgrade Cowen Outperform → Market Perform
Dec-02-22Downgrade BofA Securities Buy → Neutral $23 → $5
Dec-02-22Downgrade BofA Securities Buy → Neutral
Show Previous Ratings
Sep-01-25 09:55AM
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?
(Zacks)
Aug-13-25 01:18AM
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock
(Insider Monkey)
Aug-08-25 07:45AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
06:35AM
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Aug-07-25 05:55PM
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
07:30AM Loading…
07:30AM
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
(GlobeNewswire)
Aug-06-25 05:45PM
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates
(Zacks)
09:50AM
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
(Zacks)
Aug-05-25 08:30AM
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
(GlobeNewswire) +103.34%
Jul-30-25 05:31PM
Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight
(PR Newswire) -6.68%
Jul-24-25 12:00PM
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know
(Zacks)
Jul-22-25 07:11AM
Leptomeningeal Metastases Market Research Report 2025-2035 | Competitive Analysis of Plus Therapeutics, AstraZeneca, AngioChem, and Y-mAbs Therapeutics
(GlobeNewswire)
May-28-25 06:35AM
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
(GlobeNewswire)
May-26-25 10:57PM
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
(Insider Monkey)
10:00AM
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
(GlobeNewswire)
09:18AM Loading…
May-14-25 09:18AM
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
(TipRanks) -12.50%
03:05AM
Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
(GuruFocus.com)
May-13-25 10:29PM
Q1 2025 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
07:45AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
07:05AM
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
(GlobeNewswire)
06:35AM
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
(GlobeNewswire)
May-12-25 09:43AM
Earnings To Watch: Y-mAbs Therapeutics Inc (YMAB) Reports Q1 2025 Result
(GuruFocus.com)
08:15AM
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
May-09-25 08:35AM
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
May-07-25 06:15PM
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
(Zacks)
09:06AM
Y-mAbs gets NCCN recommendation for neuroblastoma treatment
(Seeking Alpha)
07:05AM
Y-mAbs Announces Update to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA)
(GlobeNewswire)
May-06-25 07:05AM
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
(GlobeNewswire) -9.18%
Apr-30-25 10:01AM
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline
(Zacks)
Apr-29-25 10:01AM
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
(Zacks)
03:00PM Loading…
Apr-27-25 03:00PM
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
(GlobeNewswire)
Apr-25-25 07:35AM
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
(GlobeNewswire)
Apr-11-25 04:35PM
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity
(Seeking Alpha) +11.03%
Mar-05-25 02:04AM
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ...
(GuruFocus.com)
01:34AM
Q4 2024 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Mar-04-25 07:50AM
Y-mAbs announces publication of Phase 2 interim results on naxitamab
(TipRanks)
07:45AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates
(Zacks)
06:35AM
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Mar-03-25 07:30AM
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
(GlobeNewswire) -6.65%
07:21AM
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Report Preview: What To Look For
(GuruFocus.com)
Feb-25-25 10:00AM
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
(Zacks)
Feb-20-25 04:05PM
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
(GlobeNewswire) -5.92% -5.30%
Feb-06-25 07:30AM
Y-mAbs to Present at the Oppenheimer 35 Annual Life Sciences Conference
(GlobeNewswire)
Feb-04-25 09:35AM
YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Feb-03-25 09:35AM
YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-31-25 07:35AM
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
(GlobeNewswire)
Jan-11-25 09:49AM
Y-mAbs Therapeutics Announces Strategic Business Realignment
(TipRanks)
Jan-10-25 09:26AM
Correcting and Replacing Y-mAbs Provides Strategic Business Update and 2025 Priorities
(GlobeNewswire) -6.77%
09:26AM
Correcting & Replacing Y-mAbs Provides Strategic Business Update and 2025 Priorities
(GlobeNewswire)
07:35AM
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
(GlobeNewswire)
07:05AM
Y-mAbs Provides Strategic Business Update and 2025 Priorities
(GlobeNewswire)
Jan-08-25 07:25AM
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
(TipRanks)
Dec-23-24 07:30AM
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-15-24 06:04AM
Oppenheimer Predicts Up to ~580% Jump for These 2 Strong Buy Stocks
(TipRanks)
Dec-07-24 12:00PM
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
(GlobeNewswire)
Nov-27-24 07:35AM
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference
(GlobeNewswire) +10.31%
Nov-09-24 06:01AM
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
(GuruFocus.com)
Nov-08-24 07:45AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
06:35AM
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Nov-07-24 07:08AM
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings
(GuruFocus.com)
Nov-04-24 07:35AM
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA (naxitamab-gqgk) in Japan
(GlobeNewswire)
Nov-01-24 10:00AM
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
(Zacks)
Oct-25-24 07:05AM
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
(GlobeNewswire)
Oct-09-24 06:12PM
Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ...
(GuruFocus.com)
Oct-01-24 07:05AM
Y-mAbs to Participate in Upcoming Investor Conferences in October
(GlobeNewswire)
Sep-06-24 07:30AM
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
(GlobeNewswire)
Sep-03-24 08:32AM
Y-mAbs to Participate in Upcoming Investor Conferences in September
(GlobeNewswire)
Aug-12-24 06:33PM
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
(Motley Fool) -11.24% +8.74%
07:40AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
06:30AM
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Aug-09-24 07:20AM
Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners Top Holdings Now?
(Insider Monkey)
Aug-07-24 07:05AM
Y-mAbs to Participate in Upcoming Investor Conferences in August
(GlobeNewswire)
Aug-05-24 04:05PM
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
(GlobeNewswire) -6.27%
Jul-01-24 04:05PM
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
(GlobeNewswire)
Jun-07-24 07:05AM
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
(GlobeNewswire)
Jun-05-24 07:05AM
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
(GlobeNewswire) +5.91%
Jun-01-24 08:15AM
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
(GlobeNewswire)
08:05AM
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
(GlobeNewswire)
May-09-24 11:58AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
(Insider Monkey) -5.44%
03:04AM
Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
(GuruFocus.com)
May-08-24 09:57PM
Q1 2024 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) -20.92%
May-07-24 09:55PM
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
(InvestorPlace)
06:12PM
Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates
(GuruFocus.com)
05:55PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:05PM
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Apr-26-24 07:05AM
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
(GlobeNewswire)
Apr-25-24 04:05PM
Y-mAbs to Present at 2024 ASCO Annual Meeting
(GlobeNewswire)
Mar-28-24 09:55AM
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
(Zacks)
Mar-20-24 07:37AM
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
(Zacks)
Mar-14-24 09:05AM
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
(GlobeNewswire) -5.30%
Mar-12-24 09:55AM
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
(Zacks)
Mar-05-24 12:00PM
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
(Zacks)
Mar-04-24 08:45AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript
(Insider Monkey) -7.28%
07:30AM
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
(GlobeNewswire)
Mar-01-24 09:42PM
Q4 2023 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) +11.92%
Feb-29-24 05:25PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
04:37PM
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023
(GuruFocus.com)
04:05PM
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Feb-22-24 10:00AM
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
(Zacks)
Feb-16-24 07:30AM
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
(GlobeNewswire)
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gad ThomasCHIEF BUSINESS OFFICERJun 03 '25Option Exercise2.00103,000206,000305,721Jun 05 07:17 PM
Rossi Michael JPRESIDENT & CEOMar 07 '25Sale5.203,91720,368137,083Mar 11 08:17 PM
Gad ThomasCHIEF BUSINESS OFFICERMar 07 '25Sale5.2310,81056,536202,721Mar 11 08:15 PM
Rajah VigneshOfficerMar 07 '25Proposed Sale5.204,94625,743Mar 07 04:40 PM
Smith Susan LauraOfficerMar 07 '25Proposed Sale5.265,52829,100Mar 07 04:36 PM
Gad ThomasOfficerMar 07 '25Proposed Sale5.2310,81056,547Mar 07 04:32 PM
Rossi Michael JOfficerMar 07 '25Proposed Sale5.203,91720,388Mar 07 04:26 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 19 '24Option Exercise4.3822,831100,000181,531Sep 20 04:15 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.